Bortezomib for Injection 3.5mg/Vial recall — Reliance Life Sciences Private Ltd (Class II)

Reliance Life Sciences Private Ltd is recorded by the U.S. Food and Drug Administration (FDA) as recalling Bortezomib for Injection 3.5mg/Vial — a Class II recall, initiated 2026-06-24 and posted to the FDA enforcement report on 2026-07-15, under recall number D-0673-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Sterility Assurance”. From the product description, the form is for injection and the strengths given are 3.5mg/Vial and 10 mL. 1 National Drug Code number is printed in the record: 70069-0836-01. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in N/A, India. The FDA files it under event ID 99312 together with 3 other recall numbers, all listed and linked below. Within that event this is the strength 3.5mg/Vial · 10 mL, ndc 70069-0836-01 and product named Bortezomib for Injection 3.5mg/Vial configuration; the sibling records differ on strength, ndc and product named and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0673-2026
FDA event ID 99312 (4 recall numbers)
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Reliance Life Sciences Private Ltd
Recall initiated 2026-06-24
Reported by FDA 2026-07-15
Report lag 21 days from initiation to report
Distribution Nationwide in the USA — Nationwide (US)
Firm location on record N/A, India
Product description (source) Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01

Reason reported by FDA

Lack of Sterility Assurance

4 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

5 identifying values matched by exact pattern in the 24-word product description above; each is a literal substring of it.

Product named Bortezomib for Injection 3.5mg/Vial
Form for Injection
Strength 3.5mg/Vial · 10 mL
NDC 70069-0836-01
Manufactured for Somerset Therapeutics, LLC.

Which configuration this record is

4 recall numbers share event 99312. They differ on strength, ndc and product named and agree on everything else the source states, so those are the values to check a package against.

Attribute This record (D-0673-2026) D-0671-2026D-0672-2026D-0674-2026
Strength 3.5mg/Vial · 10 mL 100mg/Vial · 10 mL500mg/Vial · 50 mL100mg/Vial · 10 mL
NDC 70069-0836-01 70069-0834-0170069-0835-0170069-0857-01
Product named Bortezomib for Injection 3.5mg/Vial Pemetrexed for Injection 100mg/VialPemetrexed for Injection 500mg/VialAzacitidine for Injection 100mg/Vial

Shared across all 4 records under this event: form for Injection; fda tier Class II; recalling firm Reliance Life Sciences Private Ltd; reason text Lack of Sterility Assurance; initiated 2026-06-24; reported 2026-07-15.

Event context: 4 recall numbers under event 99312

One enforcement action, 4 recall numbers: the FDA filed 3 further configurations of this action under event 99312. Each keeps its own recall number and dates.

Recall recordRecall numberFDA tierStrength / formNDCReported
Pemetrexed for Injection 100mg/VialD-0671-2026Class II100mg/Vial · for Injection70069-0834-012026-07-15
Pemetrexed for Injection 500mg/VialD-0672-2026Class II500mg/Vial · for Injection70069-0835-012026-07-15
Azacitidine for Injection 100mg/VialD-0674-2026Class II100mg/Vial · for Injection70069-0857-012026-07-15

Other Class II recalls with India on record

27 indexed records carry India as the recalling firm's country, against a dataset that is predominantly United States. These are the ones that also share this recall's FDA tier.

Recall recordRecall numberRecalling firmStrength / formReported
Methohexital Sodium for Injection, 500 mgD-0662-2026Onesource Specialty Pharma Ltd500 mg · for Injection2026-07-15
Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9), 1 KGD-0691-2026Shimoga Chemicals1 KG2026-07-15
Lacosamide Tablets, 100mgD-0626-2026Annora Pharma Private Ltd100mg · Tablets2026-07-01
Chlorthalidone Tablets, 25 mgD-0610-2026Inventia Healthcare Ltd25 mg · Tablets2026-06-24
Lucky Super Soft, 1%D-0629-2026Dabur India Ltd1% · Cream2026-06-24
Lucky Super Soft, 400 unitsD-0630-2026Dabur India Ltd400 units · Ointment2026-06-24

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Medline Remedy Specialized Silicone Cream (Hydraguard-D ), 59 mLD-0663-2026Biomed Laboratories, Llc.Class II2026-07-15
Methohexital Sodium, 100 mg/10 mLD-0664-2026Quva Pharma, Inc.Class II2026-07-15
Gasco Isopropyl Alcohol 70%D-0665-2026Gasco Industrial Corp.Class II2026-07-15
Gasco Isopropyl Alcohol 70%D-0666-2026Gasco Industrial Corp.Class II2026-07-15
Gasco Isopropyl Alcohol 70%D-0667-2026Gasco Industrial Corp.Class II2026-07-15
Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%D-0668-2026Gasco Industrial Corp.Class II2026-07-15
Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%D-0669-2026Gasco Industrial Corp.Class II2026-07-15
Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%D-0670-2026Gasco Industrial Corp.Class II2026-07-15

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 99312 returns all 4 of these recall numbers; a search on D-0673-2026 returns only this configuration. Match a package against 70069-0836-01 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Reliance Life Sciences Private Ltd (4 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0673-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0673-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-15
Ingested
2026-08-22
Record hash
b15b55e8bfc9488c

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.